Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Lung Cancer Therapeutics Market 

5.1. COVID-19 Landscape: Lung Cancer Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Lung Cancer Therapeutics Market, By Therapy Type

8.1. Lung Cancer Therapeutics Market, by Therapy Type, 2023-2032

8.1.1. Radiation Therapy

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Targeted Therapy

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Immunotherapy

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Chemotherapy

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Lung Cancer Therapeutics Market, By Lung Cancer Type

9.1. Lung Cancer Therapeutics Market, by Lung Cancer Type, 2023-2032

9.1.1. Small Cell Lung Cancer

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Non-small Cell Lung Cancer

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Lung Carcinoid Tumor

9.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Lung Cancer Therapeutics Market, By Distribution Channel Type 

10.1. Lung Cancer Therapeutics Market, by Distribution Channel Type, 2023-2032

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Lung Cancer Therapeutics Market, By Type of Molecule

11.1. Lung Cancer Therapeutics Market, by Type of Molecule, 2023-2032

11.1.1. Small molecules

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Biologics

11.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Lung Cancer Therapeutics Market, By Drug Class

12.1. Lung Cancer Therapeutics Market, by Drug Class, 2023-2032

12.1.1. Alkylating Agents

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Antimetabolites

12.1.2.1. Market Revenue and Forecast (2020-2032)

12.1.3. Multikinase Inhibitors

12.1.3.1. Market Revenue and Forecast (2020-2032)

12.1.4. Mitotic Inhibitors

12.1.4.1. Market Revenue and Forecast (2020-2032)

12.1.5. EGFR Inhibitors

12.1.5.1. Market Revenue and Forecast (2020-2032)

12.1.6. Others

12.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global Lung Cancer Therapeutics  Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.1.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.1.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.1.5. Market Revenue and Forecast, by Drug Class (2020-2032)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.1.6.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.1.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.1.6.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.1.7. Market Revenue and Forecast, by Drug Class (2020-2032) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.1.8.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.1.8.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.1.8.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.1.8.5. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.2.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.4. Market Revenue and Forecast, by Type of Molecule (2020-2032) 

13.2.5. Market Revenue and Forecast, by Drug Class (2020-2032) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.2.6.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.7. Market Revenue and Forecast, by Type of Molecule (2020-2032) 

13.2.8. Market Revenue and Forecast, by Drug Class (2020-2032) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.2.9.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.2.9.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.10. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.2.11. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.2.12.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.2.12.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.12.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.2.13. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.2.14.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.2.14.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.14.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.2.15. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.3.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.3.5. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.3.6.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.6.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.3.7. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.3.8.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.3.8.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.8.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.3.9. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.3.10.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.3.10.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.10.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.3.10.5. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.3.11.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.3.11.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.11.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.3.11.5. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.4.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.4.5. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.4.6.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.6.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.4.7. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.4.8.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.4.8.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.8.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.4.9. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.4.10.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.4.10.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.10.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.4.10.5. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.4.11.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.4.11.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.11.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.4.11.5. Market Revenue and Forecast, by Drug Class (2020-2032)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.5.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.5.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.5.5. Market Revenue and Forecast, by Drug Class (2020-2032)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.5.6.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.5.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.5.6.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.5.7. Market Revenue and Forecast, by Drug Class (2020-2032)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Therapy (2020-2032)

13.5.8.2. Market Revenue and Forecast, by Lung Cancer (2020-2032)

13.5.8.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.5.8.4. Market Revenue and Forecast, by Type of Molecule (2020-2032)

13.5.8.5. Market Revenue and Forecast, by Drug Class (2020-2032)

Chapter 14. Company Profiles

14.1. AstraZeneca

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. BoehringerIngelheim

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Bristol-Myers Squibb Company

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Eli Lilly and Company

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Hoffmann-La Roche

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Merck & Co

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Pfizer Inc.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Allergan Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. TevaPharmaceutical Industries Ltd.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Abbvie, Inc.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

14.11. Johnson & Johnson

14.11.1. Company Overview

14.11.2. Product Offerings

14.11.3. Financial Performance

14.11.4. Recent Initiatives

14.12. Amgen Inc.

14.12.1. Company Overview

14.12.2. Product Offerings

14.12.3. Financial Performance

14.12.4. Recent Initiatives

14.13. Novartis AG

14.13.1. Company Overview

14.13.2. Product Offerings

14.13.3. Financial Performance

14.13.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms